期刊文献+

176例ALT或AST异常的HIV/AIDS病人中医药干预分析 被引量:1

An intervention study of traditional Chinese medicine (TCM) for abnormal ALT or AST in 176HIV/AIDS patients
原文传递
导出
摘要 目的分析肝功能转氨酶异常的艾滋病病毒(HIV)感染者/艾滋病(AIDS)病人(简称HIV/AIDS病人),经中医药连续治疗2年后其临床特征变化。方法收集国家中医药治疗艾滋病试点项目(云南)临床信息数据库中,176例肝功能转氨酶异常的HIV/AIDS病人,对其在中医药干预治疗前后5个时间点(0、6、12、18、24个月),丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)进行观察分析。结果病人在中医药干预后6个月、12个月、18个月、24个月,ALT异常患者的比例从100%降低至43.8%、53.5%、42.1%和46.1%,AST异常患者的比例从100%降低至55.2%、51.1%、43.0%和50.4%,差异有统计学意义(P<0.01);ALT大于正常值上限2倍及其以上异常的构成比,从治疗前的28.3%降低至治疗后的17.9%、17.1%(第6、24个月)。结论中医药治疗艾滋病可一定程度降低HIV/AIDS病人的肝功能转氨酶异常,尤其对ALT的作用较为明显。 Objective To analyze the clinical characteristics of abnormal hepatic transaminase in patients with HIV/AIDS treated by traditional Chinese medicine (TCM) for two years. Methods Data were collected from 176 HIV/AIDS patients with abnormal hepatic transaminases in the clinical information database of TCM Treatment of AIDS Pilot Project (Yunnan). ALT and AST at the five points of TCM intervention (0, 6, 12, 18 and 24 months) were analyzed. Results At 6 months, 12 months, 18 months and 24 months of TCM intervention, ALT abnormal rate dropped to 43.8%, 53.5%, 42. 1% and 46.1% from 100%, and AST abnormal rate reduced to 55.2%, 51.1%, 43.0%, and 50.4% from 100%, respectively, suggesting a significant difference (p 〈0.01). The proportion of ALT greater than 2 times the upper limit of normal decreased from 28.3% at baseline to 17.9% and 17.1% at 6 and 24 months after treatment. Conclusion TCM may to some extent reduce the abnormality of hepatic trans- aminases in HIV/AIDS patients, especially for ATL.
出处 《中国艾滋病性病》 CAS 2014年第8期556-558,共3页 Chinese Journal of Aids & STD
关键词 艾滋病 肝功能异常 转氨酶 中医药 AIDS Abnormal liver function Transaminase Traditional Chinese medicine
  • 相关文献

参考文献3

二级参考文献15

  • 1田鄂,左利容,李丽苹.病毒性肝炎流行情况分析[J].中国实用医药,2007,2(9):124-126. 被引量:4
  • 2丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 3无.慢性乙型肝炎防治指南[J].实用肝脏病杂志,2006,9(1):8-18. 被引量:825
  • 4王爱霞,王福生,王清玥,王健,冯铁建,卢洪洲,孙洪清,孙永涛,叶寒辉,李太生,李兴旺,刘正印,邢玉兰,何云,汪宁,吴昊,吴南屏,张福杰,周曾全,宫恩聪,赵红心,赵敏,唐小平,徐莲芝,徐小元,曹韵贞,康来仪,蒋岩,蔡卫平,樊庆泊,潘孝彰.艾滋病诊疗指南[J].中华传染病杂志,2006,24(2):133-144. 被引量:632
  • 5骆抗先.乙型肝炎基础和临床[M].第2版,北京:人民卫生出版社,2003,221. 被引量:1
  • 6Mariannes S,Francois R,Philppe C,et al. Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus Infected Patients[J]. Antimicrobial Agents and Chemotherapy, 2000,12 : 3451-- 3455. 被引量:1
  • 7Marina N. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management[J]. Journal of Hepatology, 2006,44 : 132-- 139. 被引量:1
  • 8Sulkowski MS, Benhamou Y. Therapeutic Issues in HIV/HCV- Coinfected patients[J]. Journal of Viral Hepatitis, 2007, 14 (6) : 371--386. 被引量:1
  • 9Marina N,Pilar R,Luz MC,et al. Role of Hepatitis C Virus Genotype in the Development of Severe Transaminase Elevation After the Introduction of Antiretroviral Therapy [J].AIDS, 2002,30 : 65 --68. 被引量:1
  • 10Lodenyo H,Schoub B,Ally R,et al.Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital,Johannesburg[J].East Afr Med J,2000,77(1):13-15. 被引量:1

共引文献17

同被引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部